FDA-approved options include Wegovy (semaglutide, chronic weight management), Ozempic (semaglutide, type 2 diabetes), Zepbound (tirzepatide, chronic weight management), and Mounjaro (tirzepatide, type 2 diabetes)
Semaglutide targets the GLP-1 pathway, while Tirzepatide works on both GLP-1 and GIP pathways to provide broader support for appetite control and metabolism
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry
Wegovy is a once-weekly injectable weight loss medication containing semaglutide, a GLP-1 receptor agonist approved for chronic weight management
This is where the real due diligence lives - because CareBareRX, like all compliant telehealth platforms, operates through three distinct entities that each have specific, limited roles
doi: 10.1016/j.ajcnut.2022.11.007, 232